Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.41 |
| ▸ | BCR | P11274 | 8/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18696180 | 0.73 | ABL1 (0.42) | ABL1BCRP2RX3CHRNA7EPHX2 | |
| SCHEMBL19666706 | 0.65 | ABL1 (0.54) | ABL1BCR | |
| SCHEMBL16374017 | 0.63 | ABL1 (0.46) | ABL1BCRP2RX3CHRNA7EPHX2 | |
| SCHEMBL28844993 | 0.60 | ABL1 (0.41) | ABL1BCRP2RX3CHRNA7EPHX2 | |
| SCHEMBL1923201 | 0.60 | MAPT (0.61) | ABL1BCRCHRNA7EPHX2NPC1 | |
| SCHEMBL3194551 | 0.60 | MAPT (0.61) | ABL1BCRCHRNA7EPHX2NPC1 | |
| SCHEMBL18696182 | 0.59 | EPHX2 (0.35) | ABL1BCRP2RX3CHRNA7EPHX2 | |
| SCHEMBL5452795 | 0.59 | MAPT (0.51) | ABL1BCRP2RX3EPHX2RAB9A | |
| SCHEMBL3399307 | 0.58 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL6289309 | 0.58 | MAPT (0.55) | EPHX2RAB9AL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | BCR, ABL1, ABL2 | ABL1 2/4885BCR 1/4885P2RX3 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.